Genes related to anticancer drug sensitization by PARP inhibitors for colorectal cancer
| Project/Area Number |
17K09389
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Mamoru Tanaka 名古屋市立大学, 医薬学総合研究院(医学), 助教 (80617861)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
片岡 洋望 名古屋市立大学, 医薬学総合研究院(医学), 教授 (40381785)
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | PARP阻害剤 / MGMT / TMZ / MSI / ＴＭＺ / ＭＧＭＴ / ＭＳＩ / テモゾロミド / Mismatch repair(MMR) |
|---|
| Outline of Final Research Achievements |
PARP inhibitors are drugs that induce cell death by synthetic lethality, and are attracting attention as next-generation antitumor drugs due to their "excellent tumor selectivity" and "low toxicity", but the effect of the single agent is not sufficient. So, it is necessary to consider more effective treatment methods. We have reported that temozolomide (TMZ) is a candidate for a concomitant drug with a PARP inhibitor and its synergistic effect. In addition, the effects of MGMT expression and MSI susceptibility on TMZ monotherapy have been reported. In this study, we will analyze in detail the genes related to PARP inhibitors and TMZ susceptibility in colorectal cancer. We also aimed to establish clinically personalized treatment of PARP inhibitor TMZ for colorectal cancer by analyzing the expression and mutation of related genes using clinical specimens.
|
| Academic Significance and Societal Importance of the Research Achievements |
TMZの抗腫瘍作用，さらにPARP阻害剤による増感作用に．また，臨床検体を用い大腸癌組織におけるMGMT修復，ミスマッチ修復の意義について検討することはPARP阻害剤による消化器癌治療を臨床応用するための重要な研究であると考える．
|
Report
(5 results)
Research Products
(17 results)
